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Background: Despite its common occurrence, the influence of 
malignant pleural effusion (MPE) on the outcomes of patients with 
advanced non–small-cell lung cancer (NSCLC) with distant metasta-
sis (M1b) is unknown. We evaluated the clinical characteristics asso-
ciated with MPE at presentation and the prognostic impact of MPE 
at presentation in patients with stage M1b NSCLC.
Methods: We extracted data from the Surveillance Epidemiology 
and End Results (SEER) registry from patients with NSCLC diag-
nosed between 2004 and 2005. Odds-ratio estimates were calculated 
using logistic regression, and the Kaplan–Meier method was used 
to estimate the overall survival. Cox proportional hazard model was 
used to evaluate whether MPE was an independent risk for outcome.
Results: Among the 57,685 patients, MPE was present in 9170 
(15.9%), including 3944 out of 31,506 (12.5%) without distant 
metastases and 5226 (20.0%) out of 26,179 with M1b. The prob-
ability of MPE was higher in patients with larger tumors, medias-
tinal lymph node involvement, and adenocarcinoma, NSCLC not 
otherwise specified, or large-cell histology. In patients with stage 
M1b, median overall survival (3 months versus 5 months), estimated 
1-year survival (12.6% versus 24.8%), and 2-year survival (5.4% 
versus 11.3%) were significantly lower in patients with MPE com-
pared with those without MPE (hazards ratio 1.49, 95% confidence 
interval 1.44–1.54, p < 0.0001). MPE was also an independent factor 
for worse survival in multivariate analysis (hazards ratio 1.36, 95% 
confidence interval1.30–1.43, p < 0.001).
Conclusions: MPE is a common complication in patients with 
NSCLC and is associated with decreased survival in patients with 
distant metastases. If these data are validated, subsequent studies in 
patients with advanced NSCLC may consider stratification according 
to the MPE status.
Key Words: Malignant pleural effusion, Lung cancer, Stage IV.
(J Thorac Oncol. 2012;7: 1485–1489)
Malignant pleural effusion (MPE), defined by the pres-ence of malignant cells in the pleural space, indicates 
advanced disease, and is associated with significant morbid-
ity.1 MPE is a common complication of malignancies, with 
an estimated incidence of more than 150,000 cases annually.2 
Although any malignancy may involve the pleura, the most 
common causes for MPE are lung cancer (37.5%), breast can-
cer (16.8%), and lymphoma (11.5%).3 It is estimated that 8% 
to 15% of patients with lung cancer have MPE.4,5
Because of the significantly inferior overall survival 
(OS) compared with other patients with T4 disease, according 
to previous stage classifications, MPE was moved from the 
T4 (stage IIIB) to M1a (stage IV) category in the 7th edition 
of the Tumor Node Metastasis classification.6,7 Moreover, the 
treatment of patients with MPE without distant metastases is 
the same (chemotherapy) as that for patients with non–small-
cell lung cancer (NSCLC) and distant metastases.
Despite the common occurrence of MPE, most studies 
evaluating its epidemiology and demographic characteristics are 
small, retrospective, and were conducted decades ago. In addi-
tion, although MPE is a known poor prognostic factor in patients 
without metastatic disease, it remains unknown whether the 
presence of MPE is associated with worse outcomes in patients 
with distant disease (M1b). We conducted a Surveillance, 
Epidemiology and End Results (SEER) survey to evaluate the 
characteristics of patients with MPE because of NSCLC and its 
prognostic impact in patients with stage M1b disease.
METHODS
We searched the SEER-17 registry data for patients with 
non-small cell lung cancer, aged 21 years or older, with active 
follow-up, and diagnosed between 2004 and 2005. MPE was 
defined as collaborative stage extension code 72. The histology 
was coded according to the International Classification of 
Diseases for Oncology (ICD-0-3) into adenocarcinoma 
(8140–8147, 8255, 8260, 8310, 8323, 8480, 8481, 8490, 8550, 
8572), bronchioloalveolar carcinoma (BAC) (8250–8254), 
squamous cell carcinoma (8050–8052, 8070–8078), large-cell 
carcinoma (8012–8014), large-cell neuroendocrine carcinoma 
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(8013), and other histologies, including undifferentiated 
tumors (8020–8022) and carcinomas not otherwise specified 
(NOS) (8010). Demographic variables were defined as age at 
diagnosis, sex, race, histology, tumor size, tumor status (T), 
and lymph node status (N). Age groups were subdivided into 
21 to 60 years, 61 to 70 years, 71 to 80 years, and older than 80 
years. Tumor size was subdivided into 0 to 3 cm, 3.1 to 5 cm, 
5.1 to 7 cm, and 7.1 to 20 cm to match the new American Joint 
Committee on Cancer staging for T1, T2a, T2b, and T3.
Statistical Analysis
Odds ratios (OR) were calculated by logistic regression. 
OS, defined as time from diagnosis to death from any cause, 
was estimated using the Kaplan–Meier product method and 
compared by the log-rank test. Cox proportional hazards mod-
els were used to find hazard ratios adjusted for demographic 
and clinical covariates. All statistical tests were two-sided 
and p values less than 0.05 were considered to be significant. 
Statistical analyses were performed using SAS (version 9.1; 
SAS Institute, Cary, NC).
RESULTS
Demographics
The cohort was composed of 57,685 patients who met 
the inclusion criteria (Table 1). Median age at diagnosis was 
70 years (range, 21–101). Most patients were men (54.4%) 
and white (82.8%). The histologic distribution included 
23,147 patients (40.1%) with adenocarcinoma, 13,704 
(23.8%) squamous cell carcinoma, 2072 (3.6%) large-cell 
carcinoma, 15,717 (27.2%) NSCLC NOS, 177 (0.3%) undif-
ferentiated carcinoma, 2510 (4.4%) BAC, and 358 (0.6%) 
large-cell neuroendocrine carcinoma. MPE was present in 
9170 of 57,685 patients (15.9%) with NSCLC, including 
3944 of 31,506 patients (12.5%) without distant metasta-
ses and 5226 of 26,179 patients (20.0%) with M1b disease. 
Independent predictive factors for MPE in multivariate anal-
ysis included age, race, tumor size, lymph node status, and 
histology (Table 2).
Survival
Among patients without distant metastases (M0 and 
M1a), MPE was an independent predictor for worse sur-
vival (hazards ratio [HR] 1.76, 95% confidence interval [CI] 
1.65–1.87, p < 0.001). Other factors associated with survival 
in multivariate analysis included age, sex, race, histology, 
T stage, N stage, and tumor size (Table 3).
TABLE 1. Demographics for All Patients with NSCLC
Demographic Variables
Number of  
Patients (%)
Number with 
MPE (% for Each 
Variable)
Age 21–60
61–70
71–80
>80
13,248 (23.2)
17,032 (29.6)
19,374 (33.6)
7851 (13.6)
1845 (13.7)
2373 (13.9)
3067 (15.8)
1885 (24.0)
Sex Female
Male
26,275 (45.6)
31,410 (54.4)
4012 (15.3)
5158 (16.4)
Race Black
White
Am Native/Pacif
Other
6037 (10.5)
47,777 (82.8)
3766 (6.5)
105 (0.2)
1037 (17.2)
7327 915.3)
790 (21.0)
16 (15.2)
T stage T0-1
T2
T3
T4
Tx
11,285 (19.6)
16,230 (28.1)
3593 (6.2)
21,375 (37.1)
5202 (9.0)
0 (0)
0 (0)
0 (0)
9170 (43.0)
0 (0)
N stage N0
N1
N2
N3
Nx
22,871 (39.7)
4529 (7.8)
19,874 (34.5)
5501 (9.5)
4910 (8.5)
2,604 (11.4)
461 (10.2)
3968 (20.0)
992 (18.0)
1145 (23.3)
M stage M0
M1
31,506 (54.6)
26,179 (45.4)
3944 (12.5)
5226 (20.0)
Size (cm) 0–3
3.1–5
5.1–7
7.1–20
Unknown
18,540 (32.1)
13,412 (23.3)
6907 (12.0)
4894 (8.5)
13,932 (24.1)
1398 (7.5)
1582 (11.8)
981 (14.2)
841 (17.2)
4368 (31.3)
Histology Squamous
Adenocarcinoma
Large-cell
NSCLC NOS
Undifferentiated
BAC
LNEC
13,704 (23.8)
23,147 (40.1)
2027 (3.6)
15,717 (27.2)
177 (0.3)
2510 (4.4)
358 (0.6)
1643 (12.0)
4190 (18.1)
332 (16.0)
2776 (17.7)
26 (14.7)
164 (6.5)
39 (10.9)
NSCL, non–small-cell lung; MPE, malignant pleural effusion; NOS, not otherwise 
specified.
TABLE 2. Predictors for MPE at Presentation in Multivariate 
Analysis for All Patients with NSCLC
Demographic Variables Odds Ratio(95% CI) p
Age (yrs) 21–60
61–70
71–80
>80
1.00
1.22 (1.12–1.34)
1.50 91.38–1.64)
2.44 (2.20–2.70)
<0.0001
<0.0001
<0.0001
Sex Female
Male
1.00
1.06 (1.00–1.13) 0.053
Race White
Black
Am Native/Pacif
Other
1.0
1.21 (1.10–1.34)
1.47 (1.32–1.64)
0.95 (0.45–2.00)
0.001
<0.001
0.89
N stage N0
N1
N2
N3
Nx
1.00
1.08 (0.95–1.24)
2.37 (2.20–2.55)
2.13 (1.91–2.39)
2.87 (2.53–3.25)
0.23
<0.001
<0.001
<0.001
Size (cm) 0–3
3.1–5
5.1–7
7.1–20
1.00
1.40 (1.30–1.52)
1.66 (1.52–1.82)
2.13 (1.93–2.34)
<0.001
<0.001
<0.001
Histology Squamous
Adenocarcinoma
Large-cell
NSCLC NOS
Undifferentiated
BAC
LNEC
1.00
1.47 (1.35–1.60)
1.35 (1.14–1.60)
1.41 (1.29–1.54)
1.35 (0.78–2.35)
0.53 (0.41–0.68)
1.00 (0.64–1.56)
<0.001
0.0005
<0.001
0.28
<0.001
0.98
MPE, malignant pleural effusion; NSCL, non–small-cell lung; CI, confidence 
interval; NOS, not otherwise specified; BAC, bronchioloalveolar carcinoma; LNEC, 
large-cell neuroendocrine carcinoma.
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There were 26,179 patients with distant disease (M1b) 
included in the survival analysis. Several demographic 
factors influenced the survival for patients with M1b in both 
univariate and multivariate analyses (Table 4). Predictors 
for poor outcomes were advanced age, male sex, black race, 
advanced T and N stage, large tumor size, and histologies 
other than adenocarcinoma or BAC. MPE was associated with 
decreased median OS (3 months versus 5 months), estimated 
1-year survival (12.6% versus 24.8%), and 2-year survival 
(5.4% versus 11.3%) compared with those without MPE (HR 
1.49, 95% CI 1.44–1.54, p < 0.001) (Fig. 1). MPE was also an 
independent factor for worse survival in multivariate analysis 
(HR 1.36, 95% CI 1.30–1.43, p < 0.001).
DISCUSSION
The influx and exit of pleural space fluids and proteins 
are balanced to keep a constant volume in normal state. Both 
the fluid and proteins leave the pleural space through the pari-
etal pleura stomata, which are 2- to 12-µm openings between 
mesothelial cells and communicate directly to the lymphatic 
lacunae, which in turn converge into collecting lymphatics that 
drain into lymphatic channels along the ribs and subsequently 
to the mediastinal lymph nodes.8 MPE occurs mostly because of 
impaired lymphatic drainage, anywhere from tumor occlusion 
of the parietal pleura stomata to enlarged mediastinal lymph 
nodes. In patients with lung cancer, MPEs are usually caused 
by pulmonary artery invasion and embolization of tumor cells 
to the visceral pleura or direct invasion from peripheral tumors.9
Meyer et al.10 found a significant relation between medi-
astinal lymph node involvement and the development of MPE, 
whereas there was no correlation with the extent of pleural 
involvement by nodular metastases. Our study confirmed the 
importance of mediastinal lymph node involvement in the 
development of MPE, with an increased frequency of MPE 
from 10.2% to 11.4% to in patients with N0/N1 involvement 
to 18% to 20% in those with N2/N3 disease (p < 0.001).
Among NSCLC histologies, adenocarcinoma seems 
to be the most commonly associated with MPE. Irani et al.11 
reviewed 620 pleural cytology specimens from 1978 to 1982, 
finding 61 (9.8%) positive for MPE. Among the positive cytol-
ogies, lung adenocarcinoma was the most common histology 
with 25 patients (41%). Similarly, Chernow and Sahn12 found 
adenocarcinoma histology in 18 of 32 patients (56%) with lung 
cancer. Our study confirmed the increased association between 
TABLE 3. Predictors for Overall Survival in Univariate and Multivariate Analyses for Patients without Distant Disease
Demographic Variables
Univariate AnalysisHazard  
Ratio (95% CI) p
Multivariate AnalysisHazard  
Ratio(95% CI) p
MPE Absent
Present
1.00
3.51 (3.33–3.70) <0.0001
1.00
1.76 (1.65–1.87) <0.0001
Age (yrs) 21–60
61–70
71–80
>80
1.00
1.08 (1.02–1.14)
1.49 (1.41–1.57)
2.15 (2.02–2.28)
<0.0001
<0.0001
<0.0001
1.00
1.20 (1.13–1.27)
1.71 (1.62–1.80)
2.41 (2.27–2.56)
<0.0001
<0.0001
<0.0001
Sex Female
Male
1.00
1.38 (1.36–1.43) <0.0001
1.00
1.18 (1.14-1.23) <0.0001
Race White
Black
Am Native/Pacif
Other
1.00
1.24 (1.17–1.31)
0.89 (0.82–0.96)
0.78 (0.48–1.28)
0.83
<0.0001
0.19
1.00
1.14 (1.08–1.21)
0.82 (0.76–0.89)
0.90 (0.55–1.48)
<0.0001
<0.0001
0.69
T stage T0-1
T2
T3
T4
Tx
1.00
1.82 (1.73–1.90)
2.87 (2.67–3.08)
3.98 (3.79–4.18)
4.22 (3.41–5.22)
<0.0001
<0.0001
<0.0001
<0.0001
1.00
1.28 (1.20–1.36)
1.72 (1.58–1.87)
1.93 (1.80–2.07)
1.89 (1.52–2.35)
<0.0001
<0.0001
<0.0001
<0.0001
N stage N0
N1
N2
N3
Nx
1.00
1.38 (1.29–1.46)
2.50 (2.40–2.60)
2.82 (2.63–3.02)
3.08 (2.71–3.48)
0.036
<0.0001
<0.0001
<0.0001
1.00
1.19 (1.12–1.26)
1.78 (1.71–1.86)
1.96 (1.82–2.10)
1.63 (1.44–1.86)
<0.0001
<0.0001
<0.0001
<0.0001
Size (cm) 0–3
3.1–5
5.1–7
7.1–20
1.00
1.79 (1.71–1.87)
2.50 (2.38–2.63)
3.04 (2.88–3.22)
<0.0001
<0.0001
<0.0001
1.00
1.17 (1.11–1.24)
1.40 (1.32–1.50)
1.61 (1.50–1.72)
<0.0001
<0.0001
<0.0001
Histology Squamous
Adenocarcinoma
Large-cell
NSCLC NOS
Undifferentiated
BAC
LNEC
1.00
0.64 (0.61–0.66)
1.10 (1.005–1.21)
1.34 (1.28–1.40)
1.02 (0.74–1.41)
0.30 (0.27–0.33)
0.90 (0.74–1.11)
<0.0001
0.001
0.004
0.01
<0.0001
0.4
1.00
0.79 (0.75–0.82)
1.14 (1.03–1.25)
1.17 (1.12–1.23)
1.13 (0.82–1.56)
0.46 (0.42–0.52)
1.20 (0.98–1.48)
<0.0001
0.0075
<0.0001
0.47
<0.0001
0.075
MPE, malignant pleural effusion; NSCL, non–small-cell lung; CI, confidence interval; NOS, not otherwise specified; BAC, bronchioloalveolar carcinoma; LNEC, large-cell 
neuroendocrine carcinoma.
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adenocarcinoma and MPE, which may be related to the usual 
peripheral location with possible higher rates of local exten-
sion into the pleura. To further support this finding, the prob-
ability of MPE was also higher in large-cell histology, which 
also presents more commonly as a peripheral lesion, whereas 
it was lower in the typically centrally located squamous cell 
carcinoma. Nevertheless, it should be noted that 27% of the 
patients were diagnosed with NSCLC NOS. This lack of ade-
quate histological definition has been described in a recent 
SEER analysis, in which the percentage of patients diagnosed 
with NOS histology increased from 15.8% in the 1989–1994 
period to 22% and 29% in the 1995–2000 and 2000–2006 peri-
ods, respectively, being more common in elderly and stage IV 
patients diagnosed cytologically.13 In our study, the probability 
of MPE increased with each tumor size category, increasing 
significantly from 7.5% in patients with tumors between 0 and 
3 cm to 17.2% in those with tumors larger than 7 cm.
The International Association for the Study of Lung 
Cancer (IASLC) staging study showed a significantly lower 
median and 5-year OS rates for patients with MPE (8 months, 
2%) compared with those with same-lobe nodules (28 months, 
FIGURE 1. Survival in patients with M1b disease according 
to the presence of MPE M1b, distant metastasis; MPE, malig-
nant pleural effusion.
TABLE 4. Predictors for Overall Survival in Univariate and Multivariate Analyses for Patients with Distant Disease
Demographic Variables Univariate AnalysisHazard Ratio (95% CI) p Multivariate AnalysisHazard Ratio(95% CI) p
MPE Absent
Present
1.00
1.49 (1.44–1.54) <0.0001
1.00
1.36 (1.30–1.46) <0.0001
Age (yrs) 21–60
61–70
71–80
>80
1.00
1.11 (1.07–1.15)
1.28 (1.24–1.33)
1.54 (1.48–1.61)
<0.0001
<0.0001
<0.0001
1.00
1.11 (1.06–1.16)
1.32 (1.26–1.38)
1.55 (1.46–1.64)
<0.0001
<0.0001
<0.0001
Sex Female
Male
1.00
1.18 (1.15–1.21) <0.0001
1.001.17 (1.13–1.21)
<0.0001
Race White
Black
Am Native/Pacif
Other
1.00
1.00 (0.96–1.05)
0.77 (0.73–0.81)
1.49 (0.82–2.68)
0.83
<0.0001
0.19
1.00
1.05 (1.00–1.11)
0.77 (0.72–0.82)
1.61 (0.81–3.23)
0.042
<0.0001
0.18
T stage T0-1
T2
T3
T4
Tx
1.00
1.20 (1.14–1.27)
1.45 (1.35–1.55)
1.53 (1.46–1.61)
1.35 (1.28–1.43)
<0.0001
<0.0001
<0.0001
<0.0001
1.00
0.98 (0.92–1.05)
1.12 (1.03–1.22)
1.06 (1.00–1.13)
1.10 (1.02–1.20)
0.65
0.0007
0.06
0.01
N stage N0
N1
N2
N3
Nx
1.00
1.07 (1.00–1.13)
1.31 (1.27–1.36)
1.30 (1.25–1.36)
1.36 (1.30–1.42)
0.036
<0.0001
<0.0001
<0.0001
1.00
1.09 (1.02–1.17)
1.28 (1.23–1.34)
1.32 (1.25–1.40)
1.35 (1.27–1.43)
0.01
<0.0001
<0.0001
<0.0001
Size 0–3 cm
3.1–5 cm
5.1–7 cm
7.1–20 cm
1.00
1.18 (1.13–1.23)
1.34 (1.28–1.40)
1.51 (1.44–1.59)
<0.0001
<0.0001
<0.0001
1.00
1.11 (1.06–1.17)
1.21 (1.14–1.27)
1.36 (1.28–1.44)
<0.0001
<0.0001
<0.0001
Histology Squamous
Adenocarcinoma
Large-cell
NSCLC NOS
Undifferentiated
BAC
LNEC
1.00
0.97 (0.84–0.91)
1.13 (1.05–1.21)
1.06 (1.02–1.21)
1.31 (1.05–1.64)
0.47 (0.42–0.52)
0.93 (0.78–1.11)
<0.0001
0.001
0.004
0.01
<0.0001
0.4
1.00
0.92 (0.88–0.96)
1.24 (1.14–1.35)
1.11 (1.06–1.17)
1.53 (1.18–2.00)
0.54 (0.39–0.52)
1.00 (0.79–1.26)
0.0004
<0.0001
<0.0001
0.001
<0.0001
0.99
MPE, malignant pleural effusion; NSCL, non–small-cell lung; CI, confidence interval; NOS, not otherwise specified; BAC, bronchioloalveolar carcinoma; LNEC, large-cell 
neuroendocrine carcinoma.
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29%), same-side nodules (18 months, 25%), and T4 because of 
extension into mediastinal structures (13 months, 14%).14 Our 
study showed a significant prognostic role for MPE, which 
was associated with a decreased median OS from 5 months 
to 3 months in patients with stage M1b disease. This effect 
from MPE was an independent predictor for worse survival 
when adjusted for other demographic factors in a multivariate 
analysis, in which MPE was associated with a 36% increase in 
the risk of death compared with those without MPE.
Our study has several limitations. The SEER database does 
not contain information on staging procedures, use chemotherapy 
or other known prognostic factors such as performance status and 
comorbidities. Because the data are available only for newly diag-
nosed patients, it is not possible to estimate the prevalence of MPE 
in NSCLC. Nevertheless, because pleural metastases in lung can-
cer, in contrast to most other malignancies, tend to occur relatively 
early in the course of the disease, it is likely that the majority of 
MPEs in NSCLC were captured by the SEER database. We con-
firm, in this large database analysis, that MPE is more common 
in patients with adenocarcinoma histology than other histological 
subtypes of NSCLC and in patients with mediastinal lymph nodal 
involvement than without mediastinal lymph node involvement, 
findings previously observed in smaller studies.10 In addition, 
tumor size and age were found to be independent predictors for 
the development of MPE at presentation. In patients with distant 
metastases, the presence of MPE at presentation was associated 
with a significantly worse OS in multivariate analysis. If the prog-
nostic impact of MPE in patients with stage M1b NSCLC is vali-
dated, subsequent studies in patients with metastatic disease may 
require stratification according to the presence or absence of MPE.
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